Publications by authors named "Lorie A Ellis"

Claim this Profile
A
Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer.
Franklin D Gaylis, Bruno Emond, Ameur M Manceur, Anabelle Tardif-Samson, Laura Morrison, Lorie A Ellis

J Health Econ Outcomes Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis.
Julie Vanderpoel, Bruno Emond, Isabelle Ghelerter, Katherine Milbers, Marie-Hélène Lafeuille, Lorie A Ellis

Pharmacoecon Open· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study.
David P Hudesman, Soumya D Chakravarty, Bruno Emond, Lorie A Ellis, Patrick Lefebvre

BMC Rheumatol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consideration of Potential Drug-Drug Interactions in Selection of FDA-Approved Drugs Indicated for Prostate Cancer.
Dominic Pilon, Lorie A Ellis, Yongling Xiao, Ajay S Behl, Patrick Lefebvre

Am J Ther· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors.
Bruno Emond, Lorie A Ellis, Soumya D Chakravarty, Martin Ladouceur, Patrick Lefebvre

Curr Med Res Opin· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab.
Lorie A Ellis, Elisabetta Malangone-Monaco, Helen Varker, Diana Stetsovsky, Maureen Kubacki

Clinicoecon Outcomes Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A descriptive analysis of real-world treatment patterns of innovator (Remicade) and biosimilar infliximab in an infliximab-naïve Turkish population.
Yusuf Yazici, Lin Xie, Adesuwa Ogbomo, Lorie A Ellis, Kavitha Goyal

Biologics· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab.
Yusuf Yazici, Lin Xie, Adesuwa Ogbomo, Lorie A Ellis, Kavitha Goyal

Biologics· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real-world, multi-site, observational study of infusion time and treatment satisfaction with rheumatoid arthritis patients treated with intravenous golimumab or infliximab.
Shoshana R Daniel, John D McDermott, Cathy Le, Christine A Pierce, Michael A Ziskind, Lorie A Ellis

J Med Econ· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept.
Raphael J Dehoratius, Lawrence H Brent, Jeffrey R Curtis, Lorie A Ellis, Kezhen L Tang

Patient· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide.
Ajay S Behl, Lorie A Ellis, Dominic Pilon, Yongling Xiao, Patrick Lefebvre

Am Health Drug Benefits· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Evidence-Based Standards in the Treatment of Advanced Prostate Cancer in a Community Practice.
Dominic Pilon, Lorie A Ellis, Ajay S Behl, Laurence Gozalo, Bruno Emond

Urol Pract· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy.
Dominic Pilon, Ajay S Behl, Lorie A Ellis, Marie-Noëlle Robitaille, Patrick Lefebvre

Am Health Drug Benefits· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide.
Dominic Pilon, Ajay S Behl, Lorie A Ellis, Bruno Emond, Patrick Lefebvre

J Manag Care Spec Pharm· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.
Dominic Pilon, Marykay Queener, Patrick Lefebvre, Lorie A Ellis

J Med Econ· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer.
Lorie A Ellis, Marie-Hélène Lafeuille, Laurence Gozalo, Dominic Pilon, Patrick Lefebvre

Am Health Drug Benefits· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality process measures for rheumatoid arthritis: performance from members enrolled in a national health plan.
Joseph Tkacz, Lorie A Ellis, Roxanne Meyer, Susan C Bolge, Brenna L Brady

J Manag Care Spec Pharm· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis